Today is the international GIST Awareness Day!

Gastrointestinal stromal tumour (GIST) is a rare cancer that presents in various forms and can affect individuals of all ages. The prognosis for metastatic GIST is poor. All current targeted therapies rely on tyrosine kinase inhibitors, which control disease progression for a limited time before patients exhaust available treatment options. Moreover, pediatric, adolescent, wild-type, and syndromic GIST lack targeted therapy options and are primarily managed through surgeries. Therefore, there is a critical need for novel therapeutic targets beyond tyrosine kinases. This necessitates intensive research and development, which relies heavily on funding and investment to drive these essential activities. We at Sartar are committed to developing SAR003 as a novel GIST and soft tissue sarcoma therapy. SAR003 functions as a molecular glue that induces cancer cell death in PDE3A bearing tumour cells.